Segall Bryant & Hamill LLC Lowers Position in Qiagen N.V. $QGEN

Segall Bryant & Hamill LLC reduced its position in shares of Qiagen N.V. (NYSE:QGEN) by 24.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 144,789 shares of the company’s stock after selling 45,949 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.07% of Qiagen worth $6,469,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in QGEN. Lingohr Asset Management GmbH purchased a new stake in shares of Qiagen in the third quarter valued at approximately $4,218,000. Gateway Investment Advisers LLC acquired a new stake in Qiagen in the third quarter valued at $1,197,000. SG Americas Securities LLC purchased a new stake in shares of Qiagen during the 3rd quarter worth $1,032,000. Great Lakes Advisors LLC purchased a new stake in shares of Qiagen during the 3rd quarter worth $3,677,000. Finally, Allianz Asset Management GmbH grew its stake in shares of Qiagen by 53.7% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,529,224 shares of the company’s stock worth $68,028,000 after purchasing an additional 534,527 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a report on Friday, February 6th. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price target on shares of Qiagen in a report on Thursday, February 5th. JPMorgan Chase & Co. lifted their price objective on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. UBS Group set a $52.00 target price on Qiagen in a research report on Monday, February 9th. Finally, TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average price target of $55.20.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $46.81 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The business’s fifty day moving average price is $49.98 and its two-hundred day moving average price is $49.27. The stock has a market cap of $9.88 billion, a PE ratio of 23.21, a price-to-earnings-growth ratio of 2.32 and a beta of 0.70. Qiagen N.V. has a one year low of $39.92 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 earnings per share. On average, analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.